Boehringer Ingelheim Joins MIT Center for Biomedical Innovation as Founding Member

Share Article

The MIT Center for Biomedical Innovation (CBI), a collaborative "think and do" tank where academic, industry and government experts work together to transform health care innovation and delivery throughout the world, announced today that Boehringer Ingelheim Pharmaceuticals, Inc. has become a Founding Member of the Center.

The MIT Center for Biomedical Innovation (CBI), a collaborative "think and do" tank where academic, industry and government experts work together to transform health care innovation and delivery throughout the world, announced today that Boehringer Ingelheim Pharmaceuticals, Inc. has become a Founding Member of the Center.

Boehringer Ingelheim Pharmceuticals, Inc. of Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation and a member of the Boehringer Ingelheim group of companies, one of the world's largest pharmaceutical companies. It is the tenth company to sponsor CBI's collaborative efforts to foster innovation within the drug industry.

"We are pleased to welcome Boehringer Ingelheim to the growing list of partners in our unique enterprise," said Frank Douglas, MD, PhD, Executive Director of the Center. "No other academic center anywhere seeks to bring about a systemic change that works across the entire biomedical value chain, seeking to transform healthcare innovation and delivery worldwide. Boehringer Ingelheim joins the other forward-thinking companies that recognize the importance of our research and our mission."

"We are pleased to join CBI as a founding member to work with Dr. Douglas and his team along with the membership from industry, academia and government to enhance health care to the patient through innovation and increased efficiency," said Dr. Peter Farina, Sr. VP Development.

"We look forward to participating as a member of CBI at MIT and contributing to the joint mission of promoting innovation and new paradigms to the health care sector and for the benefit of all patients," said Professor Mikael Dolsten, Executive VP Worldwide Research at Boehringer Ingelheim.

The other founding sponsors are companies in the biopharmaceutical industry and include:

Altana Pharma

Amgen

AstraZeneca Pharmaceuticals

Bayer AG

Brain Resource Company

Eli Lilly & Co

Gene Logic, Inc.

Merck & Company

Novartis

Dr. Douglas added, "These companies' commitment to collaboration and innovation in the biopharm industry will enable us to move forward on an ambitious education and research agenda that we believe will transform the industry, providing solutions that enhance the safety, development, distribution and commercial value of pharmaceuticals."

CBI provides its Consortium Members and partners the opportunity to collaborate at the forefront of biomedical innovation. Participating organizations benefit from research- and education-based collaboration with other world-class industry, academic and government thought leaders.

More information about sponsorships with the Center for Biomedical Innovation can be obtained on the CBI website http://web.mit.edu/cbi or by contacting the Center at (617) 253-0183.

###

Share article on social media or email:

View article via:

Pdf Print